Advertisement

Topics

Updated analysis finds newer type of LDL-C reducing drugs still not cost-effective

07:00 EDT 22 Aug 2017 | Medical Xpress

An updated analysis of the low-density lipoprotein cholesterol (LDL-C) lowering drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, finds they are not cost-effective at current prices and that even greater price reductions than previously estimated may be needed to meet cost-effectiveness thresholds, according to a study published by JAMA.

Original Article: Updated analysis finds newer type of LDL-C reducing drugs still not cost-effective

NEXT ARTICLE

More From BioPortfolio on "Updated analysis finds newer type of LDL-C reducing drugs still not cost-effective"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Lipitor
Lipitor was the best selling drug in 2009, with the 2009 annual sales coming in at over $5m for its company, Pfizer Inc. Lipitor is the brand name for an atorvastatin calcium medication that is prescribed to lower cholesterol and triglycerides in the the...